3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
9
Terminated
3
Active not recruiting
3
Withdrawn
1
Unknown
1
Recruiting
1
Not yet recruiting
1
Approved for marketing
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
15
Endocrine
15
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
325
Lung Neoplasms
237
Small Cell Lung Carcinoma
79
Colorectal Neoplasms
30
NSCLC
25
Breast Neoplasms
22
Neoplasms
16
Adenocarcinoma of Lung
16
Disease
15
Neoplasm Metastasis
12
Stomach Neoplasms
10
Melanoma
10
Ovarian Neoplasms
9
Brain Neoplasms
9
Uterine Cervical Neoplasms
8
Triple Negative Breast Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Pleural Effusion, Malignant
8
Motor Activity
8
Mesothelioma, Malignant
8
Head and Neck Neoplasms
8
Esophageal Neoplasms
7
Endometrial Neoplasms
7
Multiple Pulmonary Nodules
6
Mesothelioma
6
Carcinoma, Hepatocellular
6
Thymoma
5
Small Cell Lung Cancer Extensive Stage
5
SCLC, Extensive Stage
5
Recurrence
5
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Thyroid Cancer, Papillary
×
Thoracic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled